An update on current pharmacotherapy options for dyspepsia

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Functional dyspepsia (FD) is a prevalent gastrointestinal disorder with significant impact on patient quality of life and socioeconomic factors.
• Current diagnostic criteria for FD, based on expert opinion, lack specificity and are often diagnosed by exclusion.
• The precise pathophysiologic mechanisms underlying FD are not fully understood, leading to diagnostic challenges.

Purpose of the Study:

• To review current pharmacologic treatments for functional dyspepsia.
• To focus on robust randomized controlled trials (RCTs) in the treatment of FD.
• To discuss evolving insights into FD pathophysiology and their impact on treatment strategies.

Main Methods:

• Literature review of randomized controlled trials (RCTs) for pharmacologic treatments of FD.
• Analysis of current understanding of FD pathophysiology.
• Synthesis of evidence regarding treatment efficacy.

Main Results:

• Pharmacologic treatment options for FD are expanding due to new insights into its pathophysiology.
• Robust RCT data is crucial for evaluating the efficacy of FD treatments.
• Despite advances, the multifactorial nature of FD presents ongoing treatment challenges.

Conclusions:

• Recent research suggests multifactorial causes for FD, including sensorimotor dysfunction, genetic factors, psychological comorbidities, food sensitivities, and immune dysregulation.
• Understanding these evolving pathophysiologic hypotheses is key to developing effective FD therapies.
• While knowledge of FD pathogenesis is growing, its clinical management remains complex.